PATHWAY is a Phase 2b/3 clinical study with an Open-Label Extension (OLE). It tests PORT-77 in patients with EPP, EPP2, and XLP. The study has three parts: P…

Erythropoietic Protoporphyria (EPP)X-Linked Protoporphyria (XLP)EPP2

~Estimated

~$10 – $8,750

Portal Therapeutics, Inc.NCT07820085

Prospective Clinical Assessment Study in Adolescents and Adults With Erythropoietic Protoporphyria (EPP) and X-Linked Porphyria (XLP) (STEPP)

The purpose of this study is to collect information about the effects of EPP/XLP in adults and adolescents. This is an observational study in which participant…

Erythropoietic Protoporphyria (EPP)X-Linked Porphyria (XLP)

~Estimated

~$10 – $1,050

Portal Therapeutics, Inc.NCT07567131